Piramal Pharma Expects EBITDA Margin Expansion In H2

Market snapshot: Piramal Pharma announced expectations of expanding its EBITDA margins during the second half of the financial year. The positive outlook follows operational momentum in Q2 FY27, backed by strong execution across CDMO and hospital generics segments.

Data Snapshot

• Q2 FY27 consolidated revenue from operations grew 28% YoY to ₹2,617 crore.
• Q2 FY27 EBITDA rose 72% YoY to ₹385 crore, expanding margins by 370 bps to 14.7%.
• Q2 FY27 Net Profit reached ₹5 crore compared to a net loss of ₹99 crore in Q2 FY26.

What's Changed

• EBITDA margin expanded to 14.7% in Q2 FY27 from 11% in Q2 FY26, gaining 370 bps YoY.
• Net profit turned positive to ₹5 crore in Q2 FY27 from a net loss of ₹99 crore in Q2 FY26.

Key Takeaways

• Operational recovery in Q2 FY27 lays a strong foundation for second-half profitability.
• EBITDA surge of 72% YoY demonstrates positive operating leverage and cost optimization.
• Business seasonality historically yields higher revenue and profitability contributions in H2.

SAHI Perspective

Piramal Pharma's management guidance for margin expansion in H2 aligns with Q2 FY27 operational results where EBITDA expanded 72% YoY. Rising RFP conversions and higher facility utilization in the CDMO business position the company to capture second-half operating leverage.

Market Implications

Anticipated H2 margin expansion reinforces market confidence in Piramal Pharma's structural earnings recovery trajectory. Continued conversion of CDMO order inflows into commercial sales will be vital for sustaining valuation momentum.

Trading Signals

Market Bias: Bullish

Q2 FY27 revenue grew 28% YoY to ₹2,617 crore alongside a 72% YoY increase in EBITDA to ₹385 crore, supporting management guidance of further margin expansion in H2.

Overweight: Pharma CDMO, Complex Hospital Generics

Trigger Factors:

• Execution of H2 FY27 EBITDA margin targets
• CDMO RFP win rates and commercial order conversion
• Sustained quarterly net profitability and debt reduction progress

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian pharmaceutical CDMO and generic drug sectors are benefiting from a recovery in global biotech funding and healthier order inflows. Operating leverage allows scaling CDMO players to achieve meaningful EBITDA margin gains during high-volume periods.

Key Risks to Watch

• Potential delays in client decision-making or commercial order execution in overseas markets.
• Raw material price volatility impacting manufacturing input costs.

Recent Developments

Piramal Pharma reported Q2 FY27 consolidated revenue of ₹2,617 crore (+28% YoY) and EBITDA of ₹385 crore (+72% YoY), with EBITDA margin expanding 370 bps to 14.7%.

Closing Insight

With Q2 FY27 performance validating operational turnaround, Piramal Pharma's ability to maintain margin momentum into H2 will determine its full-year profitability profile.

High Performance Trading with SAHI.